INBX
NASDAQInhibrx Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
News · 26 weeks47-79%
2026-04-262026-10-18
Mix2990d
- Insider13(45%)
- SEC Filings9(31%)
- Other5(17%)
- Analyst1(3%)
- Earnings1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Inhibrx Biosciences Inc.4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- PRInhibrx Announces Participation in Upcoming Scientific ConferencesSAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:2026 European Society for Medical Oncology (ESMO) CongressOctober 25th, 2026 – Madrid, SpainTitle: HexAgon-HN: a phase 2/3 study of the hexavalent OX40 agonist ordastobart (INBRX-106) in combination with pembrolizumab as first-line treatment (1L tx) of PD-L1–high recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)—phase 2 primary analysisFormat: Oral Presen
- INSIDERChief Executive Officer Lappe Mark bought $998,784 worth of shares (10,000 units at $99.88) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- INSIDERDirector Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Forsyth Douglas4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Vuori Kristiina Md4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Manhard Kimberly4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Director Kayyem Jon Faiz4/A - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Kayyem Jon Faiz bought $500,000 worth of shares (5,000 units at $100.00) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Manhard Kimberly sold $163,542 worth of shares (1,500 units at $109.03) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- INSIDERDirector Manhard Kimberly sold $115,468 worth of shares (1,000 units at $115.47) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- SECSEC Form 144 filed by Inhibrx Biosciences Inc.144 - Inhibrx Biosciences, Inc. (0002007919) (Subject)
- INSIDERDirector Kayyem Jon Faiz bought $567,580 worth of shares (5,000 units at $113.52) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERDirector Forsyth Douglas bought $286,617 worth of shares (2,500 units at $114.65) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- INSIDERChief Executive Officer Lappe Mark bought $2,645,399 worth of shares (25,000 units at $105.82) (SEC Form 4)4 - Inhibrx Biosciences, Inc. (0002007919) (Issuer)
- SECInhibrx Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Inhibrx Biosciences, Inc. (0002007919) (Filer)
- PRInhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudyFirst OX40 agonist to demonstrate clinical benefit in a randomized studyINBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab aloneResults are most pronounced in HPV+ patients, with cORR (80.0% vs 33.3%), CR rate (30.0% vs 0%), and PFS6 improvement (90.0% vs 33.0%) vs pembrolizumab aloneInhibrx will expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approvalPositive results support large expansion opportunities into highly immunogenic tumors and combination with cancer vaccinesSAN DIEGO, Sept. 8, 2026 /PRNewswire/ -- Inhibrx Biosc
- PRInhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study– Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced that it will host a live webcast presentation on Tuesday, September 8, 2026 at 5:00 a.m. Pacific Time, to provide primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab mono
- ANALYSTH.C. Wainwright initiated coverage on Inhibrx Biosciences with a new price targetH.C. Wainwright initiated coverage of Inhibrx Biosciences with a rating of Buy and set a new price target of $245.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Inhibrx Biosciences Inc.SCHEDULE 13G/A - Inhibrx Biosciences, Inc. (0002007919) (Subject)
INBX FAQ
6 questionsWhat does Inhibrx Biosciences Inc. do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcoma; and INBRX-105, an tetravalent conditional agonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc fusion protein...Where does INBX stock trade?
Inhibrx Biosciences Inc. (INBX) is listed on NASDAQ.What sector and industry is INBX in?
Inhibrx Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.What are analysts saying about INBX?
Inhibrx Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-08-24. Recent price targets cluster around $4000.00.What companies are similar to INBX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare INBX side-by-side with any of them on Quantisnow.How can I track INBX on Quantisnow?
Quantisnow aggregates Inhibrx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INBX to receive live email and push alerts on every new disclosure.